How it works:
Metformin belongs to the biguanide class and is considered a first-line therapy for type 2 diabetes. It decreases hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity. Unlike some other antidiabetic agents, it does not stimulate insulin secretion, reducing the risk of hypoglycemia when used as monotherapy.
The sustained-release (SR) formulation allows gradual release of the active substance, helping maintain stable blood glucose levels and improving gastrointestinal tolerability.
Recommended for:
Clinical evidence:
Metformin is one of the most extensively studied antidiabetic medications. Large-scale trials, including the UKPDS study, demonstrated reduced risk of diabetes-related complications and improved glycemic control.
Long-term clinical experience confirms its safety and efficacy.
Extended-release formulations have shown improved gastrointestinal tolerability compared to immediate-release forms.
Type 2 diabetes mellitus, particularly in overweight patients. Used to lower blood glucose levels, reduce insulin resistance, and help prevent diabetes-related complications. It may be used alone or in combination with other antidiabetic medications or insulin.
The tablets should be taken orally with or after meals and swallowed whole with water. Extended-release tablets must not be crushed or chewed. The dosage and duration of treatment are determined individually by a healthcare provider based on blood glucose levels and clinical response.
Contraindications:
Side effects:
